These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 22922717)
21. Assessing rheumatic disease. Hill J Nurs Times; 1991 Jan 23-29; 87(4):33-5. PubMed ID: 1990373 [No Abstract] [Full Text] [Related]
22. [Antifilaggrin antibody as a serological marker for the diagnosis of rheumatoid arthritis]. Nakazono K Nihon Rinsho; 2005 Jan; 63 Suppl 1():351-4. PubMed ID: 15799376 [No Abstract] [Full Text] [Related]
23. [Immunological and serological tests for diagnosis of rheumatoid arthritis: anti-agalactosyl IgG antibody]. Atsumi T Nihon Rinsho; 2005 Jan; 63 Suppl 1():328-31. PubMed ID: 15799372 [No Abstract] [Full Text] [Related]
24. [Anti-calpastatin antibody as a serological marker for the diagnosis of rheumatoid arthritis]. Matsuno H; Ochiai A; Iwaki-Egawa S; Watanabe Y Nihon Rinsho; 2005 Jan; 63 Suppl 1():344-50. PubMed ID: 15799375 [No Abstract] [Full Text] [Related]
25. [The new serological markers of rheumatoid arthritis]. Tuchocka-Piotrowska A; Puszczewicz M Pol Merkur Lekarski; 2007 Sep; 23(135):215-20. PubMed ID: 18080699 [TBL] [Abstract][Full Text] [Related]
26. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection. Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516 [TBL] [Abstract][Full Text] [Related]
28. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Provan SA; Semb AG; Hisdal J; Stranden E; Agewall S; Dagfinrud H; Angel K; Atar D; Kvien TK Ann Rheum Dis; 2011 May; 70(5):812-7. PubMed ID: 21288959 [TBL] [Abstract][Full Text] [Related]
29. Is it necessary to combine detection of anticitrullinated protein antibodies in the diagnosis of rheumatoid arthritis? Zhao J; Liu X; Wang Z; Liu R; Li Z J Rheumatol; 2010 Dec; 37(12):2462-5. PubMed ID: 20952480 [TBL] [Abstract][Full Text] [Related]
30. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. van Venrooij WJ; Hazes JM; Visser H Neth J Med; 2002 Nov; 60(10):383-8. PubMed ID: 12607587 [No Abstract] [Full Text] [Related]
31. Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Gao IK; Haas-Wöhrle A; Mueller KG; Lorenz HM; Fiehn C Ann Rheum Dis; 2005 Oct; 64(10):1516-7. PubMed ID: 16162906 [No Abstract] [Full Text] [Related]
32. [Anti-cyclic citrullinated peptide antibody as a serological marker for the diagnosis of rheumatoid arthritis]. Suzuki K Nihon Rinsho; 2005 Jan; 63 Suppl 1():341-3. PubMed ID: 15799374 [No Abstract] [Full Text] [Related]
33. Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort. Le Loët X; Strotz V; Lequerré T; Boumier P; Pouplin S; Mejjad O; Daragon A; Jouen F; Vittecoq O; Fardellone P; Ménard JF Rheumatology (Oxford); 2011 Oct; 50(10):1901-7. PubMed ID: 21750000 [TBL] [Abstract][Full Text] [Related]
34. [Comparative characteristics of specific autoantibodies in rheumatoid arthritis]. Lapin SV; Maslianskiĭ AL; Mazurov VI; Totolian AA Ter Arkh; 2005; 77(12):53-9. PubMed ID: 16514821 [TBL] [Abstract][Full Text] [Related]
35. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor. Yamane T; Hashiramoto A; Tanaka Y; Tsumiyama K; Miura Y; Shiozawa K; Chihara K; Shiozawa S J Rheumatol; 2008 Mar; 35(3):414-20. PubMed ID: 18203327 [TBL] [Abstract][Full Text] [Related]
36. Improvement in diagnosis of rheumatoid arthritis using dual indirect immunofluorescence and immunoblotting assays for antifilaggrin autoantibodies: a retrospective 3 year study. Ferraro-Peyret C; Tebib J; Desbos A; Bihannic R; Genestier C; Letroublon MC; Veber S; Benoit E; Veysseyre-Balter C; Monier JC; Fabien N J Rheumatol; 2002 Feb; 29(2):276-81. PubMed ID: 11838844 [TBL] [Abstract][Full Text] [Related]
37. Very early 'Rheumatoid' arthritis cohorts: limited by selection. Inanc M Rheumatology (Oxford); 2007 Feb; 46(2):185-7. PubMed ID: 17043049 [No Abstract] [Full Text] [Related]
38. Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case-control study. Berglin E; Kokkonen H; Einarsdottir E; Agren A; Rantapää Dahlqvist S Scand J Rheumatol; 2010 Nov; 39(6):454-60. PubMed ID: 20560812 [TBL] [Abstract][Full Text] [Related]
39. The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. Willemze A; van der Linden MP; le Cessie S; Trouw LA; Toes RE; Huizinga TW; van der Helm-van Mil AH Ann Rheum Dis; 2011 Sep; 70(9):1697-8. PubMed ID: 21482537 [No Abstract] [Full Text] [Related]